<DOC>
	<DOCNO>NCT02076919</DOCNO>
	<brief_summary>The purpose first-in-human study assess local ocular systemic safety tolerability LHA510 eye drop administer various concentration dose frequency .</brief_summary>
	<brief_title>First-in-Human Study LHA510 Elderly Subjects Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description>This first-in-human study conduct two part . Part 1 single ascend dose ( SAD ) design assess local ocular systemic safety tolerability single topical eye drop LHA510 administer various concentration . Four separate cohort unique elderly subject ( 55 80 year ) utilize , cohort randomize receive either topical LHA510 vehicle 3:1 ratio single dose . A disposition evaluation perform 7 day later . Part 2 multiple ascend dose ( MAD ) design assess local ocular systemic safety tolerability LHA510 administer various concentration dose frequency . Six separate cohort unique AMD subject utilized , cohort randomize receive either topical LHA510 vehicle 3:1 ratio 7 day . A disposition evaluation perform 14 day first dose study drug . A review available safety data conduct Sponsor PI ( ) prior dose escalation ( cohort progression ) . The concentration level use Part 1 Part 2 order Lowest , Next Lowest , Next Highest , Highest .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Provide write informed consent . Vital sign within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 90150 mm Hg diastolic blood pressure , 5090 mm Hg pulse rate , 40 100 bpm . Weigh least 50 kg . Able communicate well investigator . Able understand comply requirement study . Additional eligibility criterion Part 2 ( AMD subject ) : Evidence AMD one eye . Age 5590 . Other protocoldefined inclusion criterion may apply . Any currently active ocular condition require use topical eye drop . Use contact lens course study . Abnormal corneal examination result screen eligibility . History ocular surgery within past 6 month prior study participation . Use investigational drug within 30 day enrollment . History hypersensitivity allergy study drug ( include fluorescein ) drug similar chemical class . History clinically significant ECG abnormality , ECG abnormality screen eligibility . Known history current clinically significant arrhythmia . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year . Pregnant nursing ( lactate ) woman . Women childbearing potential . Use prohibit medication specify protocol . Donation loss 400 ml blood within eight ( 8 ) week prior initial dose . Low hemoglobin level screen eligibility specify protocol . Significant illness specify protocol . History drug alcohol abuse within 12 month prior dose . Additional exclusion criterion Part 1 ( healthy subject ) : Abnormal thickness central retinal subfield OCT screening . History chronic eye disease refractive error , incipient cataract , strabismic amblyopia , anisometropic amblyopia . Additional exclusion criterion Part 2 ( AMD subject ) : Any following treatment study eye within 28 day prior dose : ranibizumab ( Lucentis® ) , aflibercept ( Eylea® ) , bevacizumab ( Avastin® ) , pegaptanib ( Macugen® ) , VEGF inhibitor . Patients require received regular monthly injection drug month precede study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>LHA510</keyword>
	<keyword>First human</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Elderly</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Ocular</keyword>
	<keyword>Eye drop</keyword>
</DOC>